brexpiprazole vs cariprazine
Side-by-side comparison of brexpiprazole and cariprazine Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Rexulti
Vraylar
Rexulti is a medication used to treat certain mental health conditions. It can help with depression, schizophrenia, and agitation related to Alzheimer's disease.
Vraylar is a medicine used to treat certain mental health conditions. It can help with schizophrenia, bipolar disorder, and major depressive disorder.
Rexulti can be used with antidepressants to treat major depressive disorder in adults. It can also treat schizophrenia in adults and children 13 years and older. Additionally, Rexulti can help manage agitation in people with dementia due to Alzheimer's disease. Rexulti should not be used as needed for agitation related to dementia.
Vraylar can treat schizophrenia in adults and kids 13 and older. It also treats manic or mixed episodes of bipolar I disorder in adults and kids 10 and older. In adults, Vraylar treats the depressive episodes of bipolar I disorder. Vraylar can also be used with antidepressants to treat major depressive disorder in adults.
Rexulti affects the balance of certain natural chemicals in the brain. These chemicals, called neurotransmitters, include dopamine and serotonin. By affecting these chemicals, Rexulti can help improve mood, thinking, and behavior.
Vraylar affects certain chemicals in the brain. These chemicals are called neurotransmitters. By changing the balance of these chemicals, Vraylar can help reduce symptoms of mental health conditions.
- • Weight gain
- • Feeling sleepy
- • Restlessness or feeling like you need to move
- • Problems with muscle movement
- • Feeling restless
- • Upset stomach
- • Throwing up
- • Feeling sleepy
- Weight gain 1,673
- Using the medicine for a condition it is not approved for 1,277
- Using the medicine for a condition it is not approved for 1,092
- The medicine is not working 929
- Restlessness or feeling like you need to move 854
- Using the medicine for something it is not approved for 1,017
- The medicine is not working 502
- Gaining weight 441
- Restlessness 395
- Feeling worried or nervous 354
Elderly patients with dementia-related psychosis who are treated with antipsychotic drugs have an increased risk of death. Rexulti is not approved to treat dementia-related psychosis unless it is related to agitation from Alzheimer's disease. Antidepressants may increase the risk of suicidal thoughts and behaviors in young adults and children. Tell your doctor right away if you have thoughts of harming yourself.
Vraylar may increase the risk of death in older adults with dementia-related psychosis. Vraylar and antidepressants can increase suicidal thoughts and behaviors in children, teens, and young adults. Tell your doctor right away if you have thoughts of harming yourself.
Tell your doctor if you are pregnant or plan to become pregnant. Babies born to mothers who take Rexulti in the last 3 months of pregnancy may have withdrawal symptoms or other problems after birth. There is a pregnancy registry to monitor outcomes in women exposed to Rexulti during pregnancy. You can contact the registry at 1-866-961-2388.
Vraylar may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. There is a pregnancy registry for women who take Vraylar during pregnancy; you can contact them at 1-866-961-2388.
Also Compare — Nearby Drugs
Compare brexpiprazole with
Compare cariprazine with
How to Read This brexpiprazole vs cariprazine Comparison
brexpiprazole is classified in the Atypical Antipsychotic drug class, while cariprazine sits within the Atypical Antipsychotic class. Because both drugs share the same classification, they are often considered interchangeable in theory — but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, brexpiprazole has 5,825 submissions while cariprazine has 2,709. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between brexpiprazole and cariprazine — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.